Rocket Pharmaceuticals, Inc. (RCKT): Price and Financial Metrics


Rocket Pharmaceuticals, Inc. (RCKT): $11.56

1.32 (+12.89%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add RCKT to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

RCKT Stock Price Chart Interactive Chart >

Price chart for RCKT

RCKT Price/Volume Stats

Current price $11.56 52-week high $49.66
Prev. close $10.24 52-week low $7.57
Day low $9.87 Volume 874,300
Day high $11.60 Avg. volume 587,371
50-day MA $12.52 Dividend yield N/A
200-day MA $21.94 Market Cap 761.09M

Rocket Pharmaceuticals, Inc. (RCKT) Company Bio


Rocket Pharmaceuticals, Inc., formerly Inotek Pharmaceuticals Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye.


RCKT Latest News Stream


Event/Time News Detail
Loading, please wait...

RCKT Latest Social Stream


Loading social stream, please wait...

View Full RCKT Social Stream

Latest RCKT News From Around the Web

Below are the latest news stories about Rocket Pharmaceuticals Inc that investors may wish to consider to help them evaluate RCKT as an investment opportunity.

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial and Operational Results

CRANBURY, N.J., February 24, 2022--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today reports financial and operational results for the fourth quarter and year ended December 31, 2021.

Yahoo | February 24, 2022

Hedge Fund and Insider Trading News: Leon Cooperman, Graticule Asset Management, Blackwells Capital, AQR Capital Management, Maverick Capital, Bridgewater Associates, Rocket Pharmaceuticals Inc (RCKT), and More

From Citizen Kane, chairman of the board Bernstein quips, its no trick to make a lot of money if what you want to do is make a lot of money. Downright laughable was Washington Posts catchy

Insider Monkey | February 11, 2022

Rocket Pharmaceuticals Announces Participation in 11th Annual SVB Leerink Global Healthcare Conference

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces Gaurav Shah, M.D., Chief Executive Officer, will participate in a fireside chat at the virtual 11th Annual SVB Leerink Global Healthcare Conference on Wednesday, Feb. 16 at 10 a.m. ET. A live audio webcast of the presentation will be available under Events in the Investors sect

Business Wire | February 10, 2022

Insider Buying: The Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) CEO & Director Just Bought 2.4% More Shares

Potential Rocket Pharmaceuticals, Inc. ( NASDAQ:RCKT ) shareholders may wish to note that the CEO & Director, Gaurav...

Yahoo | February 10, 2022

Strong Insider Buying Could Indicate a Bottom in These 2 Stocks

We saw large market declines as 2022 got started – but the real story was the increase in volatility. Especially at the beginning of February, when the market losses leveled off, daily trading was characterized by strong swings up and down. It’s a situation that puts a burden on investors, to recognize the right time to buy in for optimal profits. The key is not to try and ‘time’ it on daily trading, but to look at longer trends and future predictors. One place to find indicators toward a stock’

Yahoo | February 10, 2022

Read More 'RCKT' Stories Here

RCKT Price Returns

1-mo 9.47%
3-mo -35.24%
6-mo -51.00%
1-year -72.80%
3-year -32.63%
5-year 65.14%
YTD -47.05%
2021 -60.19%
2020 140.95%
2019 53.58%
2018 41.95%
2017 -57.21%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6013 seconds.